Rchr
J-GLOBAL ID:202101009155588668   Update date: Aug. 21, 2024

Miyamoto Ryo

ミヤモト リョウ | Miyamoto Ryo
Affiliation and department:
Job title: Assistant Professor
Research field  (1): Veterinary medicine
Research keywords  (1): Cancer molecular biology, Molecular target durgs, dog
Research theme for competitive and other funds  (2):
  • 2021 - 2023 Establishment of new therapeutic strategy using afatinib in canine head and neck squamous cell carcinoma.
  • 2019 - 2021 Identification of a new treatment target of EGFR inhibitors in canine squamous cell carcinoma
Papers (13):
  • Hiroyuki Tani, Ryo Miyamoto, Teruki Miyazaki, Shingo Oniki, Kyoichi Tamura, Makoto Bonkobara. A feline case of multiple myeloma treated with bortezomib. BMC veterinary research. 2022. 18. 1. 384-384
  • Hiroyuki Tani, Ryo Miyamoto, Tomokazu Nagashima, Masaki Michishita, Kyoichi Tamura, Makoto Bonkobara. Molecular characterization of canine SHP2 mutants and anti-tumour effect of SHP2 inhibitor, SHP099, in a xenograft mouse model of canine histiocytic sarcoma. Veterinary and comparative oncology. 2022. 20. 1. 109-117
  • Hiroyuki Tani, Ryo Miyamoto, Syunya Noguchi, Sena Kurita, Tomokazu Nagashima, Masaki Michishita, Naoko Yayoshi, Kyoichi Tamura, Makoto Bonkobara. A canine case of malignant melanoma carrying a KIT c.1725_1733del mutation treated with toceranib: a case report and in vitro analysis. BMC veterinary research. 2021. 17. 1. 147-147
  • Ryo Miyamoto, Hiroyuki Tani, Tomoyo Ikeda, Hono Saima, Kyoichi Tamura, Makoto Bonkobara. Commitment toward cell death by activation of autophagy with survivin inhibitor YM155 in two canine squamous cell carcinoma cell lines with high expression of survivin. Research in veterinary science. 2021. 135. 412-415
  • Shingo Maeda, Maho Nakazawa, Mona Uchida, Ryohei Yoshitake, Takayuki Nakagawa, Ryohei Nishimura, Ryo Miyamoto, Makoto Bonkobara, Tomohiro Yonezawa, Yasuyuki Momoi. Foxp3+ Regulatory T Cells Associated With CCL17/CCR4 Expression in Carcinomas of Dogs. Veterinary pathology. 2020. 57. 4. 497-506
more...
MISC (3):
  • 宮本 良. 今だからこそ見直したい分子標的薬「犬の分子標的薬~イマチニブとトセラニブの正しい使いどころ」. CAP Companion Animal Prctice. 2024. 39. 5. 14-23
  • 宮本良, 盆子原誠. 肥満細胞腫KIT遺伝子変異検査(犬・猫). SA Medicine BOOKS「検査・手技ガイド2019」. 2019. 734-735
  • 宮本良, 大田寛. 文献紹介 自然発症副腎皮質機能亢進症の犬における犬膵特異的リパーゼ濃度. 北海道獣医師会雑誌. 2015. 59. 7-8
Lectures and oral presentations  (8):
  • Clinical Pathology
    (2023)
  • Therapeutic effect of cyclavance on canine immune-mediated disorder
    (2023)
  • 犬の扁桃扁平上皮癌株化細胞におけるアファチニブの増殖抑制効果とその作用機序の解析
    (獣医がん分子生物学研究会 2023)
  • プレドニゾロンおよびシクロスポリンにより治療した捕捉性好中球減少症のボーダー・コリーの1例
    (日本獣医内科学アカデミー学術大会 2023)
  • 血糖値の異常が出るメカニズム 臨床編
    (日本獣医内科学アカデミー学術大会 2023)
more...
Education (2):
  • 2016 - 2020 Nippon Veterinary and Life Science University Graduate School of Veterinary Medicine and Life Science
  • 2009 - 2015 Nippon Veterinary and Life Science University Faculty of Veterinary Science School of Veterinary Medicine
Professional career (1):
  • PhD (Veterinary medicine) (Nippon Veterinary and Life Science University)
Work history (7):
  • 2024/07 - 現在 Iwate University Small animal internal medicine Assistant Professor
  • 2024/04 - 2024/06 Iwate University Iwate University Veterinary Teaching Animal Hospital Specially Appointed Assistant Professor
  • 2022/04 - 2024/03 Azabu University Veterinary Teaching Hospital Specially Appointed Teacher I
  • 2021/04 - 2022/03 Nippon Veterinary and Life Science University Department of clinical pathology Post doctor
  • 2019/04 - 2021/03 Nippon Veterinary and Life Science University Department of Clinical Pathology Japan Society for the Promotion of Science Resaerch Fellow DC2-PD
Show all
Committee career (1):
  • 2023/04 - 現在 日本獣医がん学会 臨床研究委員会
Awards (1):
  • 2014/06 - Japanese Society of Veterinary Clinical Pathology The First-place Award Establishment and characterization of a cell line from a feline histiocytic sarcoma
Association Membership(s) (2):
日本獣医がん学会 ,  獣医がん分子生物学研究会
※ Researcher’s information displayed in J-GLOBAL is based on the information registered in researchmap. For details, see here.

Return to Previous Page